Financhill
Sell
24

YBGJ Quote, Financials, Valuation and Earnings

Last price:
$0.0900
Seasonality move :
141.73%
Day range:
$0.0664 - $0.0850
52-week range:
$0.0310 - $0.5439
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.99x
P/B ratio:
--
Volume:
35K
Avg. volume:
22.1K
1-year change:
-43.08%
Market cap:
$10.2M
Revenue:
$3.5K
EPS (TTM):
-$0.02

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
YBGJ
Yubo International Biotech
-- -- -- -- --
HOLX
Hologic
$1B $1.05 -0.54% 28.19% $69.01
LNMG
Linike Medical Group
-- -- -- -- --
NUWE
Nuwellis
$2.2M -- 0.27% -- $13.00
QTRX
Quanterix
$30.3M -$0.69 -10.47% -- $11.25
VREX
Varex Imaging
$190.3M $0.04 -8.98% 16.67% $16.60
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
YBGJ
Yubo International Biotech
$0.0850 -- $10.2M -- $0.00 0% 12.99x
HOLX
Hologic
$64.62 $69.01 $14.4B 27.27x $0.00 0% 3.73x
LNMG
Linike Medical Group
$0.0292 -- $101.5K -- $0.00 0% --
NUWE
Nuwellis
$7.81 $13.00 $54.3M -- $0.00 0% 1.00x
QTRX
Quanterix
$6.05 $11.25 $234.9M -- $0.00 0% 1.74x
VREX
Varex Imaging
$7.93 $16.60 $329.2M 17.58x $0.00 0% 0.42x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
YBGJ
Yubo International Biotech
-- 0.562 -- 0.13x
HOLX
Hologic
35.28% 0.986 18.29% 2.29x
LNMG
Linike Medical Group
-- 4.401 -- --
NUWE
Nuwellis
-- -2.772 -- 1.49x
QTRX
Quanterix
-- 1.424 -- 7.31x
VREX
Varex Imaging
50.78% 1.879 115.17% 2.18x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
YBGJ
Yubo International Biotech
-- -$467.3K -- -- -11737.99% -$398.2K
HOLX
Hologic
$377.3M $37.9M 7.53% 11.45% 0.06% $129.2M
LNMG
Linike Medical Group
-- -- -- -- -- --
NUWE
Nuwellis
$1.1M -$3.1M -670.55% -670.55% -160.71% -$2.5M
QTRX
Quanterix
$16.4M -$26.4M -14.39% -14.39% -87.09% -$15.1M
VREX
Varex Imaging
$76.7M $22.1M -3.95% -7.36% 9.49% $9.8M

Yubo International Biotech vs. Competitors

  • Which has Higher Returns YBGJ or HOLX?

    Hologic has a net margin of -11740.4% compared to Yubo International Biotech's net margin of -1.73%. Yubo International Biotech's return on equity of -- beat Hologic's return on equity of 11.45%.

    Company Gross Margin Earnings Per Share Invested Capital
    YBGJ
    Yubo International Biotech
    76.29% -- -$2.1M
    HOLX
    Hologic
    37.53% -$0.08 $7.1B
  • What do Analysts Say About YBGJ or HOLX?

    Yubo International Biotech has a consensus price target of --, signalling downside risk potential of --. On the other hand Hologic has an analysts' consensus of $69.01 which suggests that it could grow by 6.79%. Given that Hologic has higher upside potential than Yubo International Biotech, analysts believe Hologic is more attractive than Yubo International Biotech.

    Company Buy Ratings Hold Ratings Sell Ratings
    YBGJ
    Yubo International Biotech
    0 0 0
    HOLX
    Hologic
    4 13 0
  • Is YBGJ or HOLX More Risky?

    Yubo International Biotech has a beta of 3.981, which suggesting that the stock is 298.105% more volatile than S&P 500. In comparison Hologic has a beta of 0.553, suggesting its less volatile than the S&P 500 by 44.736%.

  • Which is a Better Dividend Stock YBGJ or HOLX?

    Yubo International Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hologic offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Yubo International Biotech pays -- of its earnings as a dividend. Hologic pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios YBGJ or HOLX?

    Yubo International Biotech quarterly revenues are $3.5K, which are smaller than Hologic quarterly revenues of $1B. Yubo International Biotech's net income of -$435.6K is higher than Hologic's net income of -$17.4M. Notably, Yubo International Biotech's price-to-earnings ratio is -- while Hologic's PE ratio is 27.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Yubo International Biotech is 12.99x versus 3.73x for Hologic. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    YBGJ
    Yubo International Biotech
    12.99x -- $3.5K -$435.6K
    HOLX
    Hologic
    3.73x 27.27x $1B -$17.4M
  • Which has Higher Returns YBGJ or LNMG?

    Linike Medical Group has a net margin of -11740.4% compared to Yubo International Biotech's net margin of --. Yubo International Biotech's return on equity of -- beat Linike Medical Group's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    YBGJ
    Yubo International Biotech
    76.29% -- -$2.1M
    LNMG
    Linike Medical Group
    -- -- --
  • What do Analysts Say About YBGJ or LNMG?

    Yubo International Biotech has a consensus price target of --, signalling downside risk potential of --. On the other hand Linike Medical Group has an analysts' consensus of -- which suggests that it could grow by 118293.94%. Given that Linike Medical Group has higher upside potential than Yubo International Biotech, analysts believe Linike Medical Group is more attractive than Yubo International Biotech.

    Company Buy Ratings Hold Ratings Sell Ratings
    YBGJ
    Yubo International Biotech
    0 0 0
    LNMG
    Linike Medical Group
    0 0 0
  • Is YBGJ or LNMG More Risky?

    Yubo International Biotech has a beta of 3.981, which suggesting that the stock is 298.105% more volatile than S&P 500. In comparison Linike Medical Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock YBGJ or LNMG?

    Yubo International Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Linike Medical Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Yubo International Biotech pays -- of its earnings as a dividend. Linike Medical Group pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios YBGJ or LNMG?

    Yubo International Biotech quarterly revenues are $3.5K, which are larger than Linike Medical Group quarterly revenues of --. Yubo International Biotech's net income of -$435.6K is higher than Linike Medical Group's net income of --. Notably, Yubo International Biotech's price-to-earnings ratio is -- while Linike Medical Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Yubo International Biotech is 12.99x versus -- for Linike Medical Group. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    YBGJ
    Yubo International Biotech
    12.99x -- $3.5K -$435.6K
    LNMG
    Linike Medical Group
    -- -- -- --
  • Which has Higher Returns YBGJ or NUWE?

    Nuwellis has a net margin of -11740.4% compared to Yubo International Biotech's net margin of -158.3%. Yubo International Biotech's return on equity of -- beat Nuwellis's return on equity of -670.55%.

    Company Gross Margin Earnings Per Share Invested Capital
    YBGJ
    Yubo International Biotech
    76.29% -- -$2.1M
    NUWE
    Nuwellis
    56.04% -$0.69 $3.6M
  • What do Analysts Say About YBGJ or NUWE?

    Yubo International Biotech has a consensus price target of --, signalling downside risk potential of --. On the other hand Nuwellis has an analysts' consensus of $13.00 which suggests that it could grow by 5815.5%. Given that Nuwellis has higher upside potential than Yubo International Biotech, analysts believe Nuwellis is more attractive than Yubo International Biotech.

    Company Buy Ratings Hold Ratings Sell Ratings
    YBGJ
    Yubo International Biotech
    0 0 0
    NUWE
    Nuwellis
    0 0 0
  • Is YBGJ or NUWE More Risky?

    Yubo International Biotech has a beta of 3.981, which suggesting that the stock is 298.105% more volatile than S&P 500. In comparison Nuwellis has a beta of 0.281, suggesting its less volatile than the S&P 500 by 71.882%.

  • Which is a Better Dividend Stock YBGJ or NUWE?

    Yubo International Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Yubo International Biotech pays -- of its earnings as a dividend. Nuwellis pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios YBGJ or NUWE?

    Yubo International Biotech quarterly revenues are $3.5K, which are smaller than Nuwellis quarterly revenues of $1.9M. Yubo International Biotech's net income of -$435.6K is higher than Nuwellis's net income of -$3M. Notably, Yubo International Biotech's price-to-earnings ratio is -- while Nuwellis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Yubo International Biotech is 12.99x versus 1.00x for Nuwellis. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    YBGJ
    Yubo International Biotech
    12.99x -- $3.5K -$435.6K
    NUWE
    Nuwellis
    1.00x -- $1.9M -$3M
  • Which has Higher Returns YBGJ or QTRX?

    Quanterix has a net margin of -11740.4% compared to Yubo International Biotech's net margin of -67.73%. Yubo International Biotech's return on equity of -- beat Quanterix's return on equity of -14.39%.

    Company Gross Margin Earnings Per Share Invested Capital
    YBGJ
    Yubo International Biotech
    76.29% -- -$2.1M
    QTRX
    Quanterix
    54.03% -$0.53 $316.4M
  • What do Analysts Say About YBGJ or QTRX?

    Yubo International Biotech has a consensus price target of --, signalling downside risk potential of --. On the other hand Quanterix has an analysts' consensus of $11.25 which suggests that it could grow by 85.95%. Given that Quanterix has higher upside potential than Yubo International Biotech, analysts believe Quanterix is more attractive than Yubo International Biotech.

    Company Buy Ratings Hold Ratings Sell Ratings
    YBGJ
    Yubo International Biotech
    0 0 0
    QTRX
    Quanterix
    1 2 0
  • Is YBGJ or QTRX More Risky?

    Yubo International Biotech has a beta of 3.981, which suggesting that the stock is 298.105% more volatile than S&P 500. In comparison Quanterix has a beta of 1.127, suggesting its more volatile than the S&P 500 by 12.667%.

  • Which is a Better Dividend Stock YBGJ or QTRX?

    Yubo International Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Yubo International Biotech pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios YBGJ or QTRX?

    Yubo International Biotech quarterly revenues are $3.5K, which are smaller than Quanterix quarterly revenues of $30.3M. Yubo International Biotech's net income of -$435.6K is higher than Quanterix's net income of -$20.5M. Notably, Yubo International Biotech's price-to-earnings ratio is -- while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Yubo International Biotech is 12.99x versus 1.74x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    YBGJ
    Yubo International Biotech
    12.99x -- $3.5K -$435.6K
    QTRX
    Quanterix
    1.74x -- $30.3M -$20.5M
  • Which has Higher Returns YBGJ or VREX?

    Varex Imaging has a net margin of -11740.4% compared to Yubo International Biotech's net margin of 3.24%. Yubo International Biotech's return on equity of -- beat Varex Imaging's return on equity of -7.36%.

    Company Gross Margin Earnings Per Share Invested Capital
    YBGJ
    Yubo International Biotech
    76.29% -- -$2.1M
    VREX
    Varex Imaging
    36.03% $0.17 $1.1B
  • What do Analysts Say About YBGJ or VREX?

    Yubo International Biotech has a consensus price target of --, signalling downside risk potential of --. On the other hand Varex Imaging has an analysts' consensus of $16.60 which suggests that it could grow by 109.33%. Given that Varex Imaging has higher upside potential than Yubo International Biotech, analysts believe Varex Imaging is more attractive than Yubo International Biotech.

    Company Buy Ratings Hold Ratings Sell Ratings
    YBGJ
    Yubo International Biotech
    0 0 0
    VREX
    Varex Imaging
    3 1 0
  • Is YBGJ or VREX More Risky?

    Yubo International Biotech has a beta of 3.981, which suggesting that the stock is 298.105% more volatile than S&P 500. In comparison Varex Imaging has a beta of 0.697, suggesting its less volatile than the S&P 500 by 30.263%.

  • Which is a Better Dividend Stock YBGJ or VREX?

    Yubo International Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Varex Imaging offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Yubo International Biotech pays -- of its earnings as a dividend. Varex Imaging pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios YBGJ or VREX?

    Yubo International Biotech quarterly revenues are $3.5K, which are smaller than Varex Imaging quarterly revenues of $212.9M. Yubo International Biotech's net income of -$435.6K is lower than Varex Imaging's net income of $6.9M. Notably, Yubo International Biotech's price-to-earnings ratio is -- while Varex Imaging's PE ratio is 17.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Yubo International Biotech is 12.99x versus 0.42x for Varex Imaging. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    YBGJ
    Yubo International Biotech
    12.99x -- $3.5K -$435.6K
    VREX
    Varex Imaging
    0.42x 17.58x $212.9M $6.9M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Oklo Stock Double?
Will Oklo Stock Double?

Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…

Why a $5 Stock Is Suddenly a Cash Machine
Why a $5 Stock Is Suddenly a Cash Machine

If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…

Is Roku Stock Undervalued Now?
Is Roku Stock Undervalued Now?

At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
42
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Alerts

Buy
55
INKT alert for Jul 15

MiNK Therapeutics [INKT] is down 36.03% over the past day.

Sell
48
NEGG alert for Jul 15

Newegg Commerce [NEGG] is down 26.42% over the past day.

Buy
77
VBTX alert for Jul 15

Veritex Holdings [VBTX] is up 19.56% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock